Alpine Immune Sciences' (ALPN) Hold Rating Reaffirmed at TD Cowen

TD Cowen restated their hold rating on shares of Alpine Immune Sciences (NASDAQ:ALPN - Free Report) in a report issued on Tuesday morning, Benzinga reports.

ALPN has been the subject of several other research reports. Guggenheim started coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a buy rating and a $55.00 price objective for the company. Wolfe Research reiterated a peer perform rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Oppenheimer restated an outperform rating and set a $44.00 price objective (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. HC Wainwright cut Alpine Immune Sciences from a buy rating to a neutral rating in a report on Thursday, April 11th. Finally, Wedbush downgraded Alpine Immune Sciences from an outperform rating to a neutral rating in a research report on Thursday, April 11th. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $50.33.

Alpine Immune Sciences Price Performance

Shares of ALPN stock traded up $0.08 during trading hours on Tuesday, hitting $64.50. The stock had a trading volume of 2,972,551 shares, compared to its average volume of 1,878,297. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of -100.78 and a beta of 1.14. Alpine Immune Sciences has a one year low of $6.71 and a one year high of $64.57. The stock's 50-day moving average price is $37.92 and its two-hundred day moving average price is $23.86.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. The business had revenue of $30.85 million during the quarter, compared to analysts' expectations of $6.90 million. As a group, equities research analysts predict that Alpine Immune Sciences will post -1.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpine Immune Sciences

Several hedge funds have recently bought and sold shares of the business. Banque Cantonale Vaudoise purchased a new stake in Alpine Immune Sciences in the 1st quarter valued at about $798,000. HighPoint Advisor Group LLC bought a new stake in shares of Alpine Immune Sciences during the fourth quarter valued at approximately $290,000. Vanguard Group Inc. boosted its holdings in shares of Alpine Immune Sciences by 51.5% in the fourth quarter. Vanguard Group Inc. now owns 2,234,767 shares of the biotechnology company's stock valued at $42,595,000 after purchasing an additional 759,888 shares during the period. Wellington Management Group LLP grew its stake in Alpine Immune Sciences by 176.6% in the fourth quarter. Wellington Management Group LLP now owns 109,882 shares of the biotechnology company's stock worth $2,094,000 after purchasing an additional 70,151 shares in the last quarter. Finally, American International Group Inc. grew its stake in Alpine Immune Sciences by 2.2% in the fourth quarter. American International Group Inc. now owns 16,185 shares of the biotechnology company's stock worth $308,000 after purchasing an additional 343 shares in the last quarter. Institutional investors own 75.17% of the company's stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.